PCRX Pacira BioSciences Inc

Price (delayed)

$57.43

Market cap

$2.61B

P/E Ratio

66.78

Dividend/share

N/A

EPS

$0.86

Enterprise value

$3.38B

Pacira BioSciences, Inc.is the industry leader in its commitment to non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. The company's long-acting local ...

Highlights
Pacira BioSciences's gross profit has increased by 34% YoY and by 9% QoQ
The revenue has grown by 31% YoY and by 7% from the previous quarter
Pacira BioSciences's debt has soared by 84% YoY but it has decreased by 11% from the previous quarter
The company's quick ratio fell by 36% YoY but it rose by 24% QoQ
Pacira BioSciences's EPS has shrunk by 75% YoY and by 9% QoQ
The company's net income has shrunk by 74% YoY and by 8% QoQ

Key stats

What are the main financial stats of PCRX
Market
Shares outstanding
45.44M
Market cap
$2.61B
Enterprise value
$3.38B
Valuations
Price to earnings (P/E)
66.78
Price to book (P/B)
3.63
Price to sales (P/S)
4.44
EV/EBIT
39.35
EV/EBITDA
26.08
EV/Sales
5.83
Earnings
Revenue
$580.5M
EBIT
$86M
EBITDA
$129.73M
Free cash flow
$103.95M
Per share
EPS
$0.86
Free cash flow per share
$2.32
Book value per share
$15.82
Revenue per share
$12.94
TBVPS
$25.32
Balance sheet
Total assets
$1.89B
Total liabilities
$1.18B
Debt
$1B
Equity
$709.58M
Working capital
$361.95M
Liquidity
Debt to equity
1.41
Current ratio
2.19
Quick ratio
1.78
Net debt/EBITDA
5.97
Margins
EBITDA margin
22.3%
Gross margin
75%
Net margin
6.6%
Operating margin
15.1%
Efficiency
Return on assets
2.3%
Return on equity
5.4%
Return on invested capital
6.1%
Return on capital employed
5.4%
Return on sales
14.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PCRX stock price

How has the Pacira BioSciences stock price performed over time
Intraday
2.04%
1 week
6.91%
1 month
-5.31%
1 year
-6.78%
YTD
-4.55%
QTD
-24.75%

Financial performance

How have Pacira BioSciences's revenue and profit performed over time
Revenue
$580.5M
Gross profit
$435.52M
Operating income
$87.88M
Net income
$38.44M
Gross margin
75%
Net margin
6.6%
The company's operating income has surged by 80% YoY but it fell by 2.3% QoQ
Pacira BioSciences's net margin has plunged by 80% YoY and by 15% from the previous quarter
The company's net income has shrunk by 74% YoY and by 8% QoQ
PCRX's operating margin is up by 37% YoY but it is down by 9% QoQ

Growth

What is Pacira BioSciences's growth rate over time

Valuation

What is Pacira BioSciences stock price valuation
P/E
66.78
P/B
3.63
P/S
4.44
EV/EBIT
39.35
EV/EBITDA
26.08
EV/Sales
5.83
Pacira BioSciences's EPS has shrunk by 75% YoY and by 9% QoQ
PCRX's P/E is 29% above its last 4 quarters average of 51.9
PCRX's P/B is 27% below its 5-year quarterly average of 5.0 and 9% below its last 4 quarters average of 4.0
The equity has increased by 9% year-on-year but it has declined by 2.9% since the previous quarter
The revenue has grown by 31% YoY and by 7% from the previous quarter
The price to sales (P/S) is 16% lower than the 5-year quarterly average of 5.3 and 15% lower than the last 4 quarters average of 5.2

Efficiency

How efficient is Pacira BioSciences business performance
Pacira BioSciences's ROA has plunged by 82% YoY and by 18% from the previous quarter
PCRX's ROE has dropped by 79% year-on-year and by 10% since the previous quarter
Pacira BioSciences's ROIC has increased by 45% YoY but it has decreased by 8% from the previous quarter
Pacira BioSciences's return on sales has increased by 29% YoY but it has decreased by 9% QoQ

Dividends

What is PCRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PCRX.

Financial health

How did Pacira BioSciences financials performed over time
The total assets is 60% greater than the total liabilities
PCRX's total liabilities has soared by 86% YoY but it is down by 12% QoQ
The total assets is up by 47% year-on-year but it has declined by 9% since the previous quarter
Pacira BioSciences's debt is 41% more than its equity
Pacira BioSciences's debt has soared by 84% YoY but it has decreased by 11% from the previous quarter
Pacira BioSciences's debt to equity has soared by 68% YoY but it has decreased by 9% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.